Cargando…

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure

Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Nakao, Makoto, Arakawa, Sosuke, Sone, Kazuki, Sato, Hidefumi, Muramatsu, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Association of Rural Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/
https://www.ncbi.nlm.nih.gov/pubmed/34707735
http://dx.doi.org/10.2185/jrm.2021-014
_version_ 1784586106599112704
author Fujita, Kohei
Nakao, Makoto
Arakawa, Sosuke
Sone, Kazuki
Sato, Hidefumi
Muramatsu, Hideki
author_facet Fujita, Kohei
Nakao, Makoto
Arakawa, Sosuke
Sone, Kazuki
Sato, Hidefumi
Muramatsu, Hideki
author_sort Fujita, Kohei
collection PubMed
description Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and Methods: We retrospectively analyzed data from 16 patients with relapsed SCLC who were treated with topotecan monotherapy after amrubicin monotherapy at our hospital. Results: The response rate, progression-free survival, and overall survival were 0%, 32.5 days (95% confidence interval [CI] = 18–51), and 112 days (95% CI = 55–267), respectively. The most common adverse events (grade ≥3) were leukopenia (31.3%) and thrombocytopenia (31.3%), followed by anemia, anorexia, edema, and lung infections. Conclusion: The efficacy of topotecan monotherapy for relapsed SCLC after amrubicin monotherapy is inconclusive. Therefore, further studies are warranted.
format Online
Article
Text
id pubmed-8527629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Association of Rural Medicine
record_format MEDLINE/PubMed
spelling pubmed-85276292021-10-26 Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure Fujita, Kohei Nakao, Makoto Arakawa, Sosuke Sone, Kazuki Sato, Hidefumi Muramatsu, Hideki J Rural Med Original Article Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and Methods: We retrospectively analyzed data from 16 patients with relapsed SCLC who were treated with topotecan monotherapy after amrubicin monotherapy at our hospital. Results: The response rate, progression-free survival, and overall survival were 0%, 32.5 days (95% confidence interval [CI] = 18–51), and 112 days (95% CI = 55–267), respectively. The most common adverse events (grade ≥3) were leukopenia (31.3%) and thrombocytopenia (31.3%), followed by anemia, anorexia, edema, and lung infections. Conclusion: The efficacy of topotecan monotherapy for relapsed SCLC after amrubicin monotherapy is inconclusive. Therefore, further studies are warranted. The Japanese Association of Rural Medicine 2021-10-01 2021-10 /pmc/articles/PMC8527629/ /pubmed/34707735 http://dx.doi.org/10.2185/jrm.2021-014 Text en ©2021 The Japanese Association of Rural Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Original Article
Fujita, Kohei
Nakao, Makoto
Arakawa, Sosuke
Sone, Kazuki
Sato, Hidefumi
Muramatsu, Hideki
Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title_full Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title_fullStr Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title_full_unstemmed Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title_short Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
title_sort evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/
https://www.ncbi.nlm.nih.gov/pubmed/34707735
http://dx.doi.org/10.2185/jrm.2021-014
work_keys_str_mv AT fujitakohei evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure
AT nakaomakoto evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure
AT arakawasosuke evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure
AT sonekazuki evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure
AT satohidefumi evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure
AT muramatsuhideki evaluationoftopotecanmonotherapyforrelapsedsmallcelllungcancerafteramrubicinmonotherapyfailure